Launch Date
10/23/2024 at 12:00 pm EST
Credit Amount
0.5
Credit Expires
10/23/2024
Disparities in mental health diagnosis, treatment, and outcomes significantly affect racial, ethnic, and LGBTQIA+ groups. These populations face barriers such as lower diagnosis rates, inadequate treatment, and poorer outcomes compared to their White, non-LGBTQIA+ counterparts. For instance, Latine patients use mental health care at half the rate of non-Hispanic White patients, and over half of LGBTQIA+ youth who need mental health care do not receive it. Addressing these barriers is critical for improving mental health equity.
In this CME Outfitters live Q&A, expert faculty will answer questions about enhancing mental health care for underserved populations. Focus will be placed on understanding and mitigating the impact of social drivers of health (SDoH), integrating holistic treatment strategies, and employing team-based approaches. Learners will gain tools to improve diagnosis, treatment, and outcomes for racial, ethnic, and LGBTQIA+ groups, fostering equitable mental health care delivery.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant provided by Johnson & Johnson.
Primary care or emergency physicians, psychiatrists, psychologists, counselors, social workers, case managers, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, front office staff and administrators, finance staff, executives, support staff, and patients
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-072-L01-P).
This activity is designated for 0.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Dr. Jain reports the following financial relationships:
Advisory Board: Adamas Pharmaceuticals, Inc.; Alkermes; Corium, Inc.; Eisai Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Usona Institute
Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alfasigma USA, Inc.; Alkermes; Almatica Pharma, LLC; Axsome Therapeutics, Inc.; Biogen; Boehringer Ingleheim; Corium, Inc.; Cingulate; Eisai Inc.; Evidera; Impel Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica Pharmaceuticals; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc; Shire Pharmaceuticals; Sumitomo Corporation; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Transcend Therapeutics; and Viatris Inc.
Research Support: AbbVie Inc.; Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: AbbVie Inc. (Allergan); Alkermes; Almatica Pharma, LLC; Axsome Therapeutics, Inc.; Corium, Inc.; Eisai Inc.; Indivior; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Tris Pharma, Inc.; and Viatris Inc.
The following individuals have no financial relationships to disclose:
Thomas Mitchell, MSW (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
Jessica Whelan, DNP, APRN, FPMHNP-BC, RN-BC (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
BCQ-123-102324-57